Wasatch Advisors LP Has $8.29 Million Stake in Nkarta, Inc. (NASDAQ:NKTX)

Wasatch Advisors LP boosted its position in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 31.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,834,680 shares of the company's stock after buying an additional 442,125 shares during the quarter. Wasatch Advisors LP owned approximately 2.60% of Nkarta worth $8,293,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Meeder Asset Management Inc. bought a new stake in shares of Nkarta during the second quarter worth $26,000. GAMMA Investing LLC increased its position in Nkarta by 1,887.0% in the second quarter. GAMMA Investing LLC now owns 4,729 shares of the company's stock worth $28,000 after purchasing an additional 4,491 shares during the period. Forefront Analytics LLC bought a new stake in Nkarta during the 2nd quarter worth about $70,000. Intech Investment Management LLC acquired a new position in Nkarta during the 3rd quarter valued at about $74,000. Finally, SG Americas Securities LLC bought a new position in shares of Nkarta in the 3rd quarter valued at about $93,000. 80.54% of the stock is currently owned by institutional investors.

Nkarta Trading Down 4.0 %

Shares of NASDAQ:NKTX traded down $0.12 during trading on Friday, hitting $2.87. 1,175,197 shares of the company's stock traded hands, compared to its average volume of 1,202,148. The company has a 50-day moving average price of $3.54 and a 200-day moving average price of $5.10. Nkarta, Inc. has a 52 week low of $2.38 and a 52 week high of $16.24. The company has a market cap of $202.53 million, a price-to-earnings ratio of -1.53 and a beta of 0.86.

Analyst Ratings Changes

Several research firms have recently issued reports on NKTX. RODMAN&RENSHAW upgraded Nkarta to a "strong-buy" rating in a research report on Wednesday, October 9th. Raymond James upgraded Nkarta from an "outperform" rating to a "strong-buy" rating and set a $16.00 target price on the stock in a report on Wednesday, August 14th. HC Wainwright decreased their target price on Nkarta from $22.00 to $18.00 and set a "buy" rating for the company in a research report on Monday, November 11th. Rodman & Renshaw began coverage on shares of Nkarta in a research report on Wednesday, October 9th. They issued a "buy" rating and a $14.00 price target on the stock. Finally, Needham & Company LLC reduced their price objective on shares of Nkarta from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Friday, November 8th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $15.00.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.